Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer
about
A case of bone metastasis of colon cancer that markedly responded to S-1/CPT-11 combination chemotherapy and became curable by resectionThe Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic ReviewMedical management of lung cancer: Experience in ChinaPhase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.Phase I/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer.S-1 plus cisplatin: another option in the treatment of advanced head and neck cancer?Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancerA phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer.A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancerPhase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer.Phase I/II trial of a biweekly combination of S-1 plus docetaxel in patients with previously treated non-small cell lung cancer (KRSG-0601).A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site.Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer.A phase I dose escalation study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancerFeasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001.Protein and mRNA expression of folic acid-associated enzymes as biomarkers for the cytotoxicity of the thymidylate synthase-targeted drugs, pemetrexed and S-1, in non-small cell lung cancer5-Fluorouracil derivatives: a patent review.Effect of celecoxib combined with chemotherapy drug on malignant biological behaviors of gastric cancerPhase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer.S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy for stage III non-small cell lung cancer: a pilot randomized controlled trial.A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.A meta-analysis of safety and efficacy on first-line S-1 therapy in cancer patients.Phase I study of docetaxel plus S-1 combination chemotherapy for recurrent non-small cell lung cancer.Efficacy of S-1 monotherapy for non-small cell lung cancer after the failure of two or more prior chemotherapy regimens.A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer.EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancerPhase II study of S-1 in patients with advanced biliary tract cancer.S-1-containing chemotherapy for patients with non-small-cell lung cancer: A population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group.Phase I study of oral S-1 and concurrent radiotherapy in patients with head and neck cancer.Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected non-small cell lung cancer: Thoracic Oncology Research Group Study 0S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy in Chinese patients with nonsmall-cell lung cancer: A multicentre randomized controlled trial.S-1 monotherapy in a patient with cholangiolocellular carcinoma: A case report.Feasibility of adjuvant chemotherapy with S-1 consisting of a 4-week administration and a two-week rest period in patients with completely resected non-small cell lung cancer.Efficacy of S-1 in non-small cell lung cancer.The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.The combination of hyperthermia or chemotherapy with gimeracil for effective radiosensitization.
P2860
Q25257549-1547CA5D-2743-4E68-AB0E-8C0EA350C22CQ26752321-C29528E8-C5FF-4BB1-A9C0-C9D3653A564EQ26798257-419C7FB4-D242-4E97-9A57-488B1CEC9F8AQ33385378-16968FDA-5A33-4A50-8CEB-47BE4FB4977BQ33387184-8C6C0B29-7493-4066-B1A9-7229227FC761Q33389563-DA8489B4-24DC-48CB-8D45-FD5C28CA1B3EQ33390208-7BA84900-B4C8-4BCE-95F2-0DEE3214657BQ33391384-49CA7189-89A1-4F07-819E-5BBC58A7114AQ33393268-FC85418B-9CD0-4E60-B6C2-957ABEC471C8Q33402690-5FE2BCA9-336F-486E-82E4-D4A90C4AB70CQ33403083-9F59239A-65A2-4E37-A28B-A76B34649D57Q33403640-3BD63AB3-4521-4B2E-8924-63485AD0B230Q33409979-83412D08-838D-4D0C-B703-1FA7557D005BQ33423185-8FE81EB0-A7CD-4A0D-A35A-86239303153DQ33431507-2AB21745-7A67-4566-B403-CBAC20BDEA4FQ33437409-784262BA-C71A-466E-9389-3C29992745CDQ33857989-09601226-0492-4B0D-AD9C-153CEBDD249BQ34253978-8B788645-C7E3-439F-BC43-0EC83D59C617Q34733346-D9A84C1D-F002-43B7-B4E0-1B754D436144Q35004744-726E6BE1-C25F-4388-AC04-13699D17E57EQ35030387-F6B83466-5C5E-4987-B61F-8737906B5360Q35775244-AE3C4A3E-9B7C-471F-9C8E-72D77D5C18E8Q35996020-A28E39EE-7E26-433B-AFF1-6D4F0D432FE8Q36142343-C8C520B0-0265-4C1F-A350-320FC60B7AF4Q36217041-B0FED912-4F4A-4FB3-A9FE-C6A27F7D8EF7Q36609407-2FF7E958-3AA7-4FF6-B1C9-7745331F4CDEQ36610363-8AB0E125-0E8A-4C86-81C9-F2376CB8DCAFQ36646598-436E093F-F04D-4822-9253-CD63A21AFBBAQ36673543-3C2C5FE6-997C-4A3E-9A42-69485E57ABEFQ36696249-F80EA107-74F5-411C-9B1D-AD3848D74890Q36953416-51030358-3ECB-4A65-9E4F-564313CF3B9CQ37006925-A1B496EE-D452-4334-8F9B-C66BEDCCE943Q37081978-5D574F47-1E72-44E2-9D69-9E3607875A25Q37256849-ED2378FA-E998-42F1-8F31-6CBA7B808AEAQ37582068-D5A2A7A9-DCC8-4E0A-99F1-093FB63E4BA3Q37641034-4A03BA47-1DB8-43B5-B0CC-A101E3813617Q38238511-A1F3F584-8FE0-4A31-A313-43C7C4E740C3Q38473718-D52951D3-BA0F-424F-874F-A23C3A2FB3A1Q39189537-E89C8111-5DDC-4E62-A995-2F8C34B22C7AQ39398677-2C0CF093-564C-4D5A-8C86-51180FD9A1C0
P2860
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer
@ast
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer
@en
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer
@nl
type
label
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer
@ast
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer
@en
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer
@nl
prefLabel
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer
@ast
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer
@en
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer
@nl
P2093
P2860
P3181
P1476
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer
@en
P2093
K Hasegawa
K Yoshimori
M Kawahara
P2860
P2888
P304
P3181
P356
10.1038/SJ.BJC.6692031
10.1054/BJOC.2001.2031
P407
P577
2001-09-28T00:00:00Z
P6179
1019106822